Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.

Area of Science:

• Nephrology
• Immunology
• Complement System Biology

Background:

• Dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) are rare C3 glomerulopathies.
• These conditions involve alternative complement pathway dysregulation and glomerular complement deposition.
• Current treatments are lacking, often leading to end-stage renal failure.

Purpose of the Study:

• To investigate the potential of soluble CR1 (sCR1) in restoring complement regulation in C3 glomerulopathy.
• To assess the efficacy of sCR1 in preventing alternative complement pathway dysregulation.

Main Methods:

• In vitro studies using sera from DDD patients.
• In vivo studies using mice deficient in complement factor H and transgenic for human CR1.
• Short-term clinical observation in a pediatric patient with end-stage renal failure.

Main Results:

• Soluble CR1 prevented alternative pathway C3 convertase dysregulation in vitro, even with C3 nephritic factors.
• sCR1 therapy normalized serum C3 levels and cleared glomerular iC3b in deficient mice.
• Short-term use in a pediatric patient demonstrated safety and normalization of terminal complement pathway activity.

Conclusions:

• Soluble CR1 effectively re-establishes regulation of the alternative complement pathway.
• These findings support clinical trials for soluble CR1 as a potential treatment for DDD and C3GN.
• sCR1 offers a promising therapeutic strategy for C3 glomerulopathies.